Experimental Drug Combination Cleared Tumors in Mice And Left Them Resistant to The Same Cancer
A Regeneron drug combination paired with Enhertu eradicated tumors in mice and conferred lasting immunity against the same cancer, per preclinical study coverage.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Coverage from JournalArta, Oncodaily, NewsBytes, UA.NEWS, and ScienceAlert reports that an experimental drug combination cleared tumors in mice and left the animals resistant to subsequent challenges with the same cancer. The regimen pairs Enhertu, the antibody-drug conjugate trastuzumab deruxtecan, with a CD28 bispecific antibody developed by Regeneron. According to the outlets, the combination eradicated established tumors in mouse models and induced an immune memory response that protected the animals when they were later re-exposed to the same cancer cells. JournalArta identifies the Regeneron drug combination by name, while Oncodaily features commentary from Wafik El-Deiry and Dimitris Skokos discussing CD28 bispecifics and their role in enhancing Enhertu's antitumor activity. NewsBytes and UA.NEWS similarly describe the antibody and drug combination destroying tumors in mice, and ScienceAlert highlights the durability of the resistance observed after tumor clearance.
The coverage emphasizes the mechanistic novelty of engaging CD28 costimulation alongside HER2-targeted payload delivery. Oncodaily's two pieces frame the findings as exploring new frontiers in CD28 bispecific immunotherapy, with El-Deiry and Skokos providing expert context on how the bispecific format may amplify T-cell activation against HER2-positive tumors treated with Enhertu. JournalArta focuses on the Regeneron origin of the CD28 bispecific, while NewsBytes and UA.NEWS summarize the outcome in accessible language. ScienceAlert underscores the immunity aspect, noting that the mice remained resistant to the same cancer after initial tumor eradication.
The background context centers on Enhertu's established role as a HER2-directed antibody-drug conjugate used in breast, gastric, and other HER2-expressing cancers, and the emerging class of CD28 bispecific antibodies designed to provide costimulatory signals to T cells within the tumor microenvironment. Preclinical synergy between payload-carrying antibodies and T-cell engagers has been a focus of immuno-oncology research, but the reported induction of durable immune memory in mice would represent a notable advance if translatable. The involvement of Regeneron, a major biotechnology company with a track record in bispecific platforms, adds institutional weight. Coverage does not specify the mouse model used, the dosing schedule, the number of animals studied, or whether the work has been peer-reviewed or presented at a conference.
What to watch next includes any formal publication or preprint release detailing the study design, tumor models, immune profiling data, and safety signals. Regulatory or clinical development announcements from Regeneron regarding the CD28 bispecific candidate would signal translational intent. Updates from AstraZeneca and Daiichi Sankyo, the developers of Enhertu, on combination strategies with T-cell engagers are also relevant. Coverage does not yet specify timelines for IND filing, first-in-human trials, or expansion to other tumor types beyond the HER2-positive models implied by Enhertu's target.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 55m ago.
Quick answers
What drugs were combined in the mouse study?
The study combined Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate, with a CD28 bispecific antibody developed by Regeneron.
What was the key finding beyond tumor clearance?
Mice that cleared tumors remained resistant when re-challenged with the same cancer cells, indicating induced immune memory.
Has this combination been tested in humans?
Coverage does not mention human testing; the reports describe preclinical mouse study results only.
Coverage (6)
- Regeneron Drug Combination Clears Tumors in Mouse Study JournalArta · 1d ago
- Wafik El-Deiry: CD28 Bispecifics Enhance the Antitumor Activity of Trastuzumab Deruxtecan Oncodaily · 1d ago
- Enhertu with antibody eradicates tumors and induces immunity in mice NewsBytes · 1d ago
- Drug and antibody combination destroyed tumors in mice UA.NEWS · 1d ago
- Dimitris Skokos: Exploring New Frontiers in CD28 Bispecific Immunotherapy Oncodaily · 1d ago
- Experimental Drug Combination Cleared Tumors in Mice And Left Them Resistant to The Same Cancer ScienceAlert · 1d ago
Topics
Related trends
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
MedPacto reported that its experimental drug MP010 eliminated 75% to 87.5% of aggressive pancreatic tumors in mice.
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
Cancer vaccines emerge as a major focus for the N.I.H. through a newly announced public-private partnership.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
Kodiak Sciences stock soars on positive AMD trial data
Kodiak Sciences shares surged over 90% following positive Phase 3 trial results for an eye disease drug targeting AMD.